Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense paclitaxel + cisplatin as neoadjuvant therapy in operable stage II/IIIA NSCLC
2004-000804-41Phase 2Terminated
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Central European Cooperative Oncology Group. Primary endpoint: clinical response rate. Started Oct 2004; status: terminated.
02
Drugs
paclitaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000804-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000804-41.